A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

Its primary role is to manage your body’s natural sleep-wake cycle. People with low melatonin may have trouble falling or staying asleep. Alzheimer’s disease is a progressive neurodegenerative ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease ... Alzheimer's Treatment One Step ...

Half of those with hypothyroidism aren’t aware that they have it. The most common cause of hypothyroidism is Hashimoto’s disease. Natural treatments address lifestyle and environmental factors that ...

On the other hand, sleep problems like insomnia and sleep apnea can lead to serious health issues and even increase the risk ...

Researchers have discovered that suppressing a nucleolar complex can reduce Alzheimer’s-related protein toxicity. Scientists ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.